Apellis Pharmaceuticals Announces That APL-2 Met Its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-...
August 24, 2017
MaxCyte, Inc. - First Day of Dealings on AIM
March 30, 2016
Apellis Pharmaceuticals Announces Pricing of Initial Public Offering
November 8, 2017
MaxCyte to Present Novel Approach to CAR-T for Treatment of Solid Tumors at Biochemical Society in London
October 20, 2015
Gaithersburg, Maryland - MaxCyte Inc., a world leader in the discovery, development, and manufacture of innovative cell therapies, today announces that it will present its approach to addressing the problem of on-target off-tumor toxicity against normal tissue of viral vector-modified CAR T-/NK-cells to the Biochemical Society in London on 20th October 2015.
The presentation, to be made at the Biochemical Societys focused meeting on Chimeric Antigen Receptor Therapy in Haematology and Oncology: Current Successes and Challenges, will be given by Madhusudan V. Peshwa, Executive Vice President of Cellular Therapies at MaxCyte.
Dr. Peshwa will detail how MaxCyte deploys a non-viral approach using mRNA CAR transfection to permit prospective control of on-target off-tumor toxicity in multiple solid cancers. Collaborating with multiple academic groups, MaxCyte has enabled translation of mRNA CAR therapy into seven human clinical trials to preliminarily confirm safety and anti-tumor activity.
Doug Doerfler, President & CEO of MaxCyte, Inc. said: We are excited by the potential of our technology and believe that the use of mRNA has multiple advantages over viral vector technology in the delivery of CAR Therapies. In particular, we believe that our approach has the potential to reduce toxicity to normal tissue as well as target solid tumors, a significant unmet medical need. We look forward to discussing our findings with our colleagues at the Biochemical Society and the wider scientific community.